Review on the long-term effects of Immune Checkpoint Inhibitors – DKFZ German Cancer Research Center
Quoting DKFZ German Cancer Research Center on LinkedIn:
“Review on the long-term effects of Immune Checkpoint Inhibitors (ICI) therapy led by scientists at the DKFZ brings to light the enduring consequences of ICI therapy on cancer survivors’ quality of life.
Since the first approval of an ICI in 2011 for advanced melanoma treatment, these drugs have emerged as a fundamental addition to the arsenal against cancer, joining surgery, chemotherapy, and radiotherapy. ICIs work by unleashing the body’s immune system to attack cancer cells, metaphorically taking the brakes off the immune response.
While ICIs have extended the lives of many patients by years, the DKFZ team’s review of 39 studies is the first to systematically evaluate the long-term quality of life for patients post-ICI therapy outside of clinical trials. This analysis has shed light on persistent side effects, including inflammatory reactions and psychosocial challenges, that affect a significant number of cancer survivors.
Dr. Arndt’s work underscores the importance of thorough hashtag#Aftercare for ICI-treated patients and points to the need for more extensive research to address critical questions regarding fertility and the ability to return to work. Tailored aftercare and further comprehensive research are urgently needed to address the nuanced needs of the growing population of cancer survivors.
Congratulations to Deniz Can Güven, Melissa Thong, and Volker Arndt for this insightful review.”
Read further.
Source: DKFZ German Cancer Research Center/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023